A Drug Utilization Evaluation study of Amphotericin B in neutropenic patients in a teaching hospital in Iran

Iranian Journal of Pharmaceutical Research

Volumn 11, Issue 1, 2012, Pages 151-156

  Tavakoli Ardakani, Maria ^a   Eshraghi, Azadeh ^a   Talasaz, Azita Hajhossein ^b   Salamzadeh, Jamshid ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Amphotericin B; Drug Utilization Evaluation (DUE); Febrile neutropenia

Indexed keywords

AMIKACIN; AMPHOTERICIN B; VANCOMYCIN;

ANOREXIA; ASPERGILLOSIS; CANDIDIASIS; CHILL; CLINICAL ARTICLE; CLINICAL PRACTICE; DIARRHEA; DIZZINESS; DRUG INDUCED HEADACHE; FATIGUE; FEVER; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; INSOMNIA; IRAN; MUCORMYCOSIS; MYCOSIS; NAUSEA; NEUTROPENIA; PAIN; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHARMACIST; PRACTICE GUIDELINE; PROSPECTIVE STUDY; PRURITUS; REVIEW; TEACHING HOSPITAL; TREATMENT DURATION; VOMITING;

EID: 84858608092     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Kannagara S. Management of febrile neutropenia. Commun. Oncol. (2006) 3: 585-91.
2. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA and Wingard JR. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin. Infect. Dis. (2011) 52: 427-31.
3. Winston DJ, Hathorn JW, Schuster MG, Schiller GJ and Territo MC. A multicentre, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am. J. Med. (2000) 108: 282-9.
4. Kontoyiannis DP and Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet (2002) 30: 1135-44.
5. Girois SB, Chapuis F, Decullier E and Revol BG. Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Eur. J. Clin. Microbiol. Infect. Dis. (2005) 24: 119-30.
6. Fahimi F, Baniasadi S, Behzadni N, Fatemeh Varahram F and Leila Ghazi Tabatabaie LG. Enoxaparin Utilization Evaluation: an observational prospective study in medical inpatients. Iranian J. Pharm. Res. (2008) 7: 77-82.
7. Luber AD, Maa L, Lam M and Guglielmo BJ. Risk factorsfor amphotericin B-induced nephrotoxicity. J. Antimicrob. Chemother. (1999) 43: 267-71.
8. Prevention and treatment of cancer-related Infections. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. [serial online] [cited 2010 April 19], Screen]. Available from: URL:http://www.nccn.org/professionals/physician_gls/PDF/infections.pdf.
9. Stevens DA. Diagnosis of fungal infections: current status. J. Antimicrob. Chemother. (2002) 49: 11-9.
10. Sharma A and Lokeshwar N. Febrile neutropenia in haematological malignancies. J. Postgrad. Med. (2005) 51: 42-8.
11. Pablo JC. Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J. Antimicrob. Chemother. (2002) 49: 81-6.
12. Jeon GW, Koo SH, Lee JH, Hwang JH, Kim SS, Lee EK, Chang W, Chang YS, Park WS. Jeon GW, Koo SH, Lee JH, Hwang JH, Kim SS, Lee EK, Chang W, Chang YS and Park WS. A comparison of AmBisome® to amphotericin b for treatment of systemic candidiasis in very low birth weight infants. Yonsei. Med. J. (2007) 48: 619-26.
13. van Wout JW, Novakova I, Verhagen CA, Fibbe WE, de Pauw BE and van der Meer JW. The efficacy of itraconazole against systemic fungal infection in neutropenic patients: a randomized comparative study with amphotericin B. J. Infect. (1991) 22: 45-52.
14. Park SH, Choi SM, Lee DG, Choi JH, Yoo JH, Min WS and Shin WS. Intravenous itraconazole vs amphotericin B deoxycholate for the empirical antifungal therapy in patients with persistent neutropenic fever. Korean J. Intern. Med. (2006) 21: 165-72.
15. Winston DJ, Halthon JW, Schuster MG, Schiller GJ and Territo MC. A multicenter randomized trial of fluconazol vs amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am. J. Med. (2000) 108: 282-9.
16. Malik IA, MoidI, Aziz Z, Khan S and Suleman M. A randomized comparison of fluconazole with ampotericin B as empirical antifungal agents in cancer patients with prolonged neutropenia. Am. J. Med. (1998) 105: 478-83.
17. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL and Young LS. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis. (2002) 34: 730-51.
18. Laniado-Laborin R and Cabrales-Vargas MN. Amphotericin B: sideeffects and toxicity. Rev. Iberoam. Micol. (2009) 26: 223-7.
19. Fahimi F. Implementation of a clinical pharmacy education program in a teaching hospital: resident oriented documentation and intervention. Iranian J. Pharm. Res. (2010) 9: 297-302.
20. Abbasi-Nazari M, Salamzadeh J, Hajebi G and Gilbert B. The role of clinical pharmacists in educating nurses to reduce drug-food interactions (absorption phase) in hospitalized patients. Iranian J. Pharm. Res. (2011) 10: 173-178.
21. Fisher MA, Talbot GH, Maislin G, McKeon BP, Tynan KP and Strom BL. Risk factors for amphotericin B-associated nephrotoxicity. Am. J. Med. (1989) 87: 547-52.
22. Harbarth S, Pestotnik SL, Lloyd JF, Burke JP and Samore MH. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am. J. Med. (2001) 111: 528-34.